Leen Van den Steen1, Olivier Vanderveken2,3,4, Jan Vanderwegen5,6, Dirk Van Gestel7, Jean-François Daisne8, Johan Allouche6, Laurence Delacroix9, Diane Van Rompaey2, Sylvie Beauvois7, Sophie Cvilic10, Steven Mariën2, Gauthier Desuter11, Jan Baptist Vermorken3,4,12, Danielle Van den Weyngaert13, Pol Specenier3,4,12, Carl Van Laer2,3,4, Marc Peeters3,4,12, Paul Van de Heyning2,3, Gilbert Chantrain6, Georges Lawson7, Cathy Lazarus14,15, Marc De Bodt2,3,16, Gwen Van Nuffelen2,3,16. 1. Department of Otolaryngology and Head and Neck Surgery-Rehabilitation Center for Communication Disorders, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Antwerp, Belgium. Leen.Van.den.Steen@uza.be. 2. Department of Otolaryngology and Head and Neck Surgery-Rehabilitation Center for Communication Disorders, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Antwerp, Belgium. 3. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 4. Multi-disciplinary Oncological Center Antwerp, Antwerp, Belgium. 5. University College Thomas More, Antwerp, Belgium. 6. CHU Saint-Pierre, Brussels, Belgium. 7. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 8. Université Catholique de Louvain, CHU-UCL-Namur, Site Sainte-Elisabeth, Namur, Belgium. 9. Université Catholique de Louvain, CHU-UCL-Namur, Site Godinne, Yvoir, Belgium. 10. Clinique Saint-Jean Bruxelles, Bruxelles, Belgium. 11. Cliniques Universitaires St-Luc, Universite Catholique de Louvain, Brussels, Belgium. 12. Department Medical Oncology, Antwerp University Hospital, Antwerp, Belgium. 13. ZNA Multididisciplinaire Oncologie, Antwerp, Belgium. 14. Department of Otolaryngology Head & Neck Surgery, Mount Sinai Beth Israel, New York, NY, USA. 15. Department of Otorhinolaryngology of the Albert Einstein College of Medicine, Department of Otorhinolaryngology, New York, NY, USA. 16. Faculty of Speech, Pathology and Audiology, Ghent University, Ghent, Belgium.
Abstract
PURPOSE: The aim of this study was to investigate the feasibility of tongue strength measures (TSMs) and the influence of bulb location, sex, and self-perceived pain and mucositis in head and neck cancer (HNC) patients during chemoradiotherapy (CRT). METHODS: Twenty-six newly diagnosed HNC patients treated with CRT performed anterior and posterior maximal isometric tongue pressures by means of the Iowa Oral Performance Instrument (IOPI). The Oral Mucositis Weekly Questionnaire (OMWQ) and a Visual Analogue Scale (VAS) for pain during swallowing were completed weekly from baseline to 1 week post CRT. RESULTS: Feasibility of TSMs during CRT declines significantly from 96 to 100% at baseline to 46% after 6 weeks of CRT. But post-hoc analyses reveal only significant differences in feasibility between baseline and measurements after 4 weeks of treatment. No effect of gender or bulb location was established, but feasibility is influenced by pain and mucositis. CONCLUSIONS: Feasibility of TSMs declines during CRT and is influenced by mucositis and pain. For the majority of subjects, TSMs were feasible within the first 4 weeks, which provides a window of scientific and clinical opportunities in this patient population.
PURPOSE: The aim of this study was to investigate the feasibility of tongue strength measures (TSMs) and the influence of bulb location, sex, and self-perceived pain and mucositis in head and neck cancer (HNC) patients during chemoradiotherapy (CRT). METHODS: Twenty-six newly diagnosed HNC patients treated with CRT performed anterior and posterior maximal isometric tongue pressures by means of the Iowa Oral Performance Instrument (IOPI). The Oral Mucositis Weekly Questionnaire (OMWQ) and a Visual Analogue Scale (VAS) for pain during swallowing were completed weekly from baseline to 1 week post CRT. RESULTS: Feasibility of TSMs during CRT declines significantly from 96 to 100% at baseline to 46% after 6 weeks of CRT. But post-hoc analyses reveal only significant differences in feasibility between baseline and measurements after 4 weeks of treatment. No effect of gender or bulb location was established, but feasibility is influenced by pain and mucositis. CONCLUSIONS: Feasibility of TSMs declines during CRT and is influenced by mucositis and pain. For the majority of subjects, TSMs were feasible within the first 4 weeks, which provides a window of scientific and clinical opportunities in this patient population.
Entities:
Keywords:
Chemoradiotherapy; Deglutition; Dysphagia; Head and neck cancer; Mucositis; Tongue strength
Authors: Susan G Butler; Andrew Stuart; Xiaoyan Leng; Erika Wilhelm; Catherine Rees; Jeff Williamson; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2011-02-07 Impact factor: 6.053
Authors: Joel B Epstein; Jennifer L Beaumont; Clement K Gwede; Barbara Murphy; Adam S Garden; Ruby Meredith; Quynh-Thu Le; David Brizel; John Isitt; David Cella Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: Judith E Raber-Durlacher; Mike T Brennan; Irma M Verdonck-de Leeuw; Rachel J Gibson; June G Eilers; Tuomas Waltimo; Casper P Bots; Marisol Michelet; Thomas P Sollecito; Tanya S Rouleau; Aniel Sewnaik; Rene-Jean Bensadoun; Monica C Fliedner; Sol Silverman; Fred K L Spijkervet Journal: Support Care Cancer Date: 2011-12-29 Impact factor: 3.603
Authors: Leen Van den Steen; Jan Vanderwegen; Cindy Guns; Rik Elen; Marc De Bodt; Gwen Van Nuffelen Journal: Dysphagia Date: 2018-09-12 Impact factor: 3.438
Authors: Leen Van den Steen; Charlotte Schellen; Katja Verstraelen; Anne-Sophie Beeckman; Jan Vanderwegen; Marc De Bodt; Gwen Van Nuffelen Journal: Dysphagia Date: 2017-10-19 Impact factor: 3.438
Authors: Margot Baudelet; Leen Van den Steen; Fréderic Duprez; Marc De Bodt; Sarah Deschuymer; Ann Goeleven; Isabel Hutsebaut; Steven Mariën; Sabine Meersschout; Daan Nevens; Sandra Nuyts; Marc Peeters; Pol Specenier; Michiel Van den Brekel; Lisette van der Molen; Caroline Vandenbruaene; Olivier Vanderveken; Joost Van Dinther; Carl Van Laer; Tom Vauterin; Hilde Verstraete; Gwen Van Nuffelen Journal: Trials Date: 2020-03-02 Impact factor: 2.279
Authors: Margot Baudelet; Fréderic Duprez; Leen Van den Steen; Sandra Nuyts; Daan Nevens; Ann Goeleven; Caroline Vandenbruaene; Hanne Massonet; Alice Vergauwen; Heleen Bollen; Sarah Deschuymer; Kristien Wouters; Marc Peeters; Carl Van Laer; Steven Mariën; Michiel Van den Brekel; Lisette van der Molen; Tom Vauterin; Joost van Dinther; Hilde Verstraete; Isabel Hutsebaut; Sabine Meersschout; Olivier Vanderveken; Marc De Bodt; Gwen Van Nuffelen Journal: Dysphagia Date: 2022-09-19 Impact factor: 2.733